Lisa Cadoo, MD
Internal Medicine · Montclair, NJNPI 1538460498
Payments from drug & device makers
Across 153 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$264
- AstraZeneca$242
- AbbVie$212
- Novo Nordisk$208
- Takeda Pharmaceuticals U.S.A., Inc.$162
- Gilead$95
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,29498%
- Education$482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 16 | $264 |
| AstraZeneca | 16 | $242 |
| AbbVie | 15 | $212 |
| Novo Nordisk | 15 | $208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $162 |
| Gilead | 7 | $95 |
| Corcept Therapeutics | 4 | $90 |
| Teva Pharmaceuticals USA, Inc. | 6 | $82 |
| GSK | 6 | $81 |
| Amgen(2 entities) | 5 | $77 |
| Boston Scientific | 3 | $69 |
| Kyowa Kirin, Inc. | 4 | $69 |
| Bausch Health US, LLC | 4 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Phadia US Inc. | 3 | $58 |
| Merck | 4 | $55 |
| Exact Sciences | 2 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Astellas Pharma US Inc | 2 | $37 |
| Arbor Pharmaceuticals, Inc. | 3 | $37 |
| Organon | 3 | $34 |
| Lilly USA, LLC | 2 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Exeltis, USA Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Biocryst US Sales Co., LLC | 1 | $18 |
| Mylan Specialty L.p. | 1 | $16 |
| Modernatx, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Lupin Inc. | 1 | $14 |
| CSL Behring | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
How this compares
$2,342 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 13 | $27,336 |
| MounjaroTirzepatide | 15 | $19,406 |
| LinzessLinaclotide | 14 | $16,068 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 20 | $15,309 |
| FarxigaDapagliflozin Propanediol | 20 | $14,506 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 42 | $12,767 |
| EliquisApixaban | 14 | $11,398 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,762 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 17 | $3,683 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 13 | $1,729 |
| Metoprolol Succinate | 68 | $1,144 |
| Atorvastatin Calcium | 115 | $1,099 |
| Olmesartan Medoxomil | 18 | $929 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 11 | $920 |
| Levothyroxine Sodium | 88 | $867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $208 | $27,33613 claims |
| MerckJanumet Xr, Janumet | $55 | $22,07132 claims |
| Lilly USA, LLCMounjaro | $27 | $19,40615 claims |
| GSKArexvy, Shingrix | $81 | $16,45159 claims |
| AbbVieLinzess | $212 | $16,06814 claims |
| AstraZenecaFarxiga | $242 | $14,50620 claims |
| PfizerEliquis | $264 | $11,39814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Montclair
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.